Eli Lilly do Brasil Brazil
07.08.2025 - 18:02:39ANS abre Consulta Pública para avaliar incorporação de terapia-alvo para câncer de pulmão de não pequenas células avançado com fusão no gene RET
Acesso em 06/02/2025.[2] Retsevmo® (selpercatinibe). DisponÃvel em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=RETSEVMO. Acesso em 15/01/2025
[3] Pacheco FA, Paschol MEM, Carvalho MGC. Biomarcadores tumorais no câncer de pulmão: um caminho para uma terapia biológica. J Pneumol. 2002; 28(3):143-49
[4] Phase1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer? (LIBRETTO-001). DisponÃvel em: https://clinicaltrials.gov/ct2/show/NCT03157128 - Acesso em 09/01/2025
[5] Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;389(20):1839-50
[6] Dorantes-Heredia R, et al. Transl Lung Cancer Res. 2016;5:401-412
[7] National Library of Medicine - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971812/ - Acesso em Janeiro de 2024
[8] Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167
[9] Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023
[10] Vansteenkiste JF, Van De Kerkhove C, Wauters E, et al. Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2019;19(8):659-671
[11]Â Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299-311
[12] Phase1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). DisponÃvel em: https://clinicaltrials.gov/ct2/show/NCT03157128 - Acesso em janeiro de 2024
[13] ZHOU, C. et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. The New England Journal of Medicine, 2023. - LIBRETTO 431
[14]Â HADOUX, J. et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. The New England Journal of Medicine, 2023. - LIBRETTO 531
PP-SE-BR-0153 – FEVEREIRO 2025
View original content:FONTE Eli Lilly do Brasil
